Work

Abstract 356: Rezatapopt and KRAS inhibitors for the treatment of TP53 Y220C and KRAS mutant cancers.

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-356

Authors: Argun Akcakanat, Ecaterina E. Dumbrava, Kurt W. Evans, Ran Zhang, Ming Zhao, Amber Kennon, Xiaofeng Zheng, Stephen M. Scott, Erkan Yuca, Gabriela Raso, Elisabeth K. Kong, Yasmeen Rizvi, David Hong, Masha V. Poyurovsky, Guillermina Lozano, Anil Korkut, Funda Meric-Bernstam

Institutions: The University of Texas MD Anderson Cancer Center, PMV Pharmaceuticals, Inc. (United States)

Language: English

Topic: Cancer-related Molecular Pathways

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7148799722

Cites:

Cited by:

Related to: